UroEdge™

Non-Muscle-Invasive Bladder Cancer (NMIBC)

Non-muscle-invasive bladder cancer (NMIBC) is an early-stage form of bladder cancer that remains confined to the bladder lining and has not invaded the muscle layer. This educational library explores the evolving management of NMIBC through expert discussions on diagnosis, risk stratification, guideline-directed care, intravesical therapies, emerging treatment options, biomarkers, patient selection, surveillance, and multidisciplinary care.

Non-Muscle-Invasive Bladder Cancer Learning Center

TitleSpeakerExcerptDate
Beyond Symptom Management: Exploring Hydration as a Proactive Strategy to Improve the INLEXZO™ Patient ExperienceSiamak Daneshmand, MDSia Daneshmand, MD, and Paras H. Shah, MD, discuss hydration, urinary symptoms, device crystallization, and practical approaches to managing INLEXZO™ treatment. 2026-10-122026
Implementing New Bladder Cancer Therapies in Urology PracticeMark N. Painter, CPMA, MBSMark N. Painter, James M. Bienvenu, MD, and Leigh Sewell discuss the clinical, operational, and financial considerations involved in successfully implementing new bladder cancer therapies in independent urology practices. 2026-08-172026
INLEXZO™ (Gem iDRS) Reimbursement UpdateMark N. Painter, CPMA, MBSMark N. Painter explains how urology practices can successfully implement INLEXZO™ by understanding Medicare reimbursement, prior authorization, documentation requirements, predetermination, and revenue cycle management for buy-and-bill therapies. 2026-08-102026
Integrating INLEXZO™ Into Community Urology Practice: Workflow, Patient Selection, and ImplementationScott B. Sellinger, MD, FACSDr. Scott B. Sellinger, Dr. Jason M. Hafron, and Dr. Tom Jayram discuss how community urology practices can successfully integrate INLEXZO™ through patient selection, workflow development, multidisciplinary coordination, and standardized operational planning. 2026-07-292026
Optimizing Patient Management for INLEXZO™ in BCG-Unresponsive Non-Muscle Invasive Bladder CancerSam S. Chang, MD, MBADr. Sam S. Chang, Dr. Joshua J. Meeks, and Nurse Practitioner Meredith Donahue discuss practical strategies for preparing and managing patients receiving INLEXZO™ for BCG-unresponsive non-muscle invasive bladder cancer, with a focus on proactive symptom management and supportive care. 2026-07-292026
Intravesical Drug Delivery System (Gem-iDRS) in NMIBCSiamak Daneshmand, MDPanel discussion on Gem-iDRS and SunRISe-1 data in BCG-unresponsive NMIBC.2026-05-082026
INLEXZO™ J Code UpdateDavid S. Morris, MD, FACSA permanent J9183 code for INLEXZO standardizes reimbursement and supports broader NMIBC access.2026-04-012026